Multicenter phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma

✍ Scribed by Nozomi Niitsu; Masataka Okamoto; Mika Kohori; Sadao Aoki; Ikuo Miura; Masami Hirano

• Publisher: John Wiley and Sons
• Year: 2006
• Tongue: English
• Weight: 169 KB
• Volume: 24
• Category: Article
• ISSN: 0278-0232
• DOI: 10.1002/hon.793

✦ Synopsis

Abstract

We treated elderly patients (65–69 years) who had aggressive lymphoma with the CyclOBEAP regimen, and we studied the safety and efficacy of this treatment. The CyclOBEAP regimen was administered over a total period of 12 weeks. Doxorubicin 40 mg/m^2^ was given every 2 weeks in combination with either cyclophosphamide 800 mg/m^2^ or etoposide 70 mg/m^2^ qd × 3. During the alternate weeks, non‐myelosuppressive vincristine 1.0 mg/m^2^ was given either with bleomycin 10 mg/m^2^ or alone. Prednisolone 40 mg/m^2^ was administered daily for three 14‐day periods during weeks 1–2, 5–6 and 9–10. There were 51 eligible patients. A complete response was achieved in 42 patients (82%). The 5‐year overall survival (OS) rate was 60.6% and progression‐free survival (PFS) rate was 51.8%. WHO grade 4 neutropenia was observed in 32 patients and thrombocytopenia in 8 patients. We showed that the CyclOBEAP regimen can be safely used in the treatment of aggressive lymphoma in elderly patients and it achieved a high rate of remission. Copyright © 2006 John Wiley & Sons, Ltd.